Trial Profile
A Multinational, Multicenter, Randomized, Placebo-controlled, Parallel Group, Double-Blind, Phase 3 Trial to Evaluate the Efficacy and Safety of Gemigliptin 50 mg q.d Compared With Placebo Added to Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin Alone or on Insulin in Combination With Metformin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemigliptin (Primary) ; Insulin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ZEUS II
- Sponsors LG Life Sciences
- 20 Feb 2018 Status changed from not yet recruiting to completed.
- 18 Jul 2016 New trial record